Data Reinforce The Value Of UFT As An Important Treatment Option For Patients With Metastatic Colorectal Cancer
Data presented at this year’s European Congress of Clinical Oncology (ECCO) demonstrate that a novel combination regimen based on Merck Serono’s oral 5-fluorouracil (5-FU) therapy UFT® (tegafur-uracil) plus leucovorin (LV) results in a high response rate in the first-line treatment of metastatic colorectal cancer (mCRC).
